The use of interferon in the treatment of multiple myeloma

John J. Costanzi, Richard B Pollard

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Almost all patients with multiple myeloma still relapse or become refractory in 2 to 3 years. Interferon (IFN) therapy has clearly influenced the levels of abnormal serum proteins in some patients. A multiinstitutional phase II clinical trial used alfa-2b recombinant interferon (Intron A, Schering, Kenilworth, NJ) in 38 evaluable patients with relapsing and refractory multiple myeloma; two thirds of the patient population had received extensive prior treatment. Seven responded, of whom three continued to do so beyond 1 year-one with an ongoing complete remission. An additional 13 had at least a 25% decrease in abnormal paraproteins. Of nine patients who were initially refractory to chemotherapy, two responded to IFN. Of nine relapsing patients returned to chemotherapy following IFN therapy, six then responded. Thirty previously untreated patients with multiple myeloma were treated with IFN followed by melphalan and prednisone; of 24 evaluable patients, 18 responded with a median duration of 10+ months. Alfa-2b IFN apparently does not antagonize melphalan or prednisone, nor does it appear to worsen the response of the two drugs alone. Effectiveness of recombinant alfa-2b IFN in pretreated relapsing patients suggests additional trials are needed to study its effects in previously untreated patients. A significant number of patients who relapsed on their original chemotherapy and subsequent interferon will apparently respond to the reinstitution of chemotherapy.

Original languageEnglish (US)
Pages (from-to)24-28
Number of pages5
JournalSeminars in Oncology
Volume14
Issue number2 SUPPL. 2
StatePublished - 1987
Externally publishedYes

Fingerprint

Multiple Myeloma
Interferons
interferon alfa-2b
Therapeutics
Drug Therapy
Melphalan
Prednisone
Paraproteins
Phase II Clinical Trials
Blood Proteins
Recurrence

ASJC Scopus subject areas

  • Oncology

Cite this

The use of interferon in the treatment of multiple myeloma. / Costanzi, John J.; Pollard, Richard B.

In: Seminars in Oncology, Vol. 14, No. 2 SUPPL. 2, 1987, p. 24-28.

Research output: Contribution to journalArticle

Costanzi, John J. ; Pollard, Richard B. / The use of interferon in the treatment of multiple myeloma. In: Seminars in Oncology. 1987 ; Vol. 14, No. 2 SUPPL. 2. pp. 24-28.
@article{186eb1da492d4399b940152fa4493c73,
title = "The use of interferon in the treatment of multiple myeloma",
abstract = "Almost all patients with multiple myeloma still relapse or become refractory in 2 to 3 years. Interferon (IFN) therapy has clearly influenced the levels of abnormal serum proteins in some patients. A multiinstitutional phase II clinical trial used alfa-2b recombinant interferon (Intron A, Schering, Kenilworth, NJ) in 38 evaluable patients with relapsing and refractory multiple myeloma; two thirds of the patient population had received extensive prior treatment. Seven responded, of whom three continued to do so beyond 1 year-one with an ongoing complete remission. An additional 13 had at least a 25{\%} decrease in abnormal paraproteins. Of nine patients who were initially refractory to chemotherapy, two responded to IFN. Of nine relapsing patients returned to chemotherapy following IFN therapy, six then responded. Thirty previously untreated patients with multiple myeloma were treated with IFN followed by melphalan and prednisone; of 24 evaluable patients, 18 responded with a median duration of 10+ months. Alfa-2b IFN apparently does not antagonize melphalan or prednisone, nor does it appear to worsen the response of the two drugs alone. Effectiveness of recombinant alfa-2b IFN in pretreated relapsing patients suggests additional trials are needed to study its effects in previously untreated patients. A significant number of patients who relapsed on their original chemotherapy and subsequent interferon will apparently respond to the reinstitution of chemotherapy.",
author = "Costanzi, {John J.} and Pollard, {Richard B}",
year = "1987",
language = "English (US)",
volume = "14",
pages = "24--28",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 2",

}

TY - JOUR

T1 - The use of interferon in the treatment of multiple myeloma

AU - Costanzi, John J.

AU - Pollard, Richard B

PY - 1987

Y1 - 1987

N2 - Almost all patients with multiple myeloma still relapse or become refractory in 2 to 3 years. Interferon (IFN) therapy has clearly influenced the levels of abnormal serum proteins in some patients. A multiinstitutional phase II clinical trial used alfa-2b recombinant interferon (Intron A, Schering, Kenilworth, NJ) in 38 evaluable patients with relapsing and refractory multiple myeloma; two thirds of the patient population had received extensive prior treatment. Seven responded, of whom three continued to do so beyond 1 year-one with an ongoing complete remission. An additional 13 had at least a 25% decrease in abnormal paraproteins. Of nine patients who were initially refractory to chemotherapy, two responded to IFN. Of nine relapsing patients returned to chemotherapy following IFN therapy, six then responded. Thirty previously untreated patients with multiple myeloma were treated with IFN followed by melphalan and prednisone; of 24 evaluable patients, 18 responded with a median duration of 10+ months. Alfa-2b IFN apparently does not antagonize melphalan or prednisone, nor does it appear to worsen the response of the two drugs alone. Effectiveness of recombinant alfa-2b IFN in pretreated relapsing patients suggests additional trials are needed to study its effects in previously untreated patients. A significant number of patients who relapsed on their original chemotherapy and subsequent interferon will apparently respond to the reinstitution of chemotherapy.

AB - Almost all patients with multiple myeloma still relapse or become refractory in 2 to 3 years. Interferon (IFN) therapy has clearly influenced the levels of abnormal serum proteins in some patients. A multiinstitutional phase II clinical trial used alfa-2b recombinant interferon (Intron A, Schering, Kenilworth, NJ) in 38 evaluable patients with relapsing and refractory multiple myeloma; two thirds of the patient population had received extensive prior treatment. Seven responded, of whom three continued to do so beyond 1 year-one with an ongoing complete remission. An additional 13 had at least a 25% decrease in abnormal paraproteins. Of nine patients who were initially refractory to chemotherapy, two responded to IFN. Of nine relapsing patients returned to chemotherapy following IFN therapy, six then responded. Thirty previously untreated patients with multiple myeloma were treated with IFN followed by melphalan and prednisone; of 24 evaluable patients, 18 responded with a median duration of 10+ months. Alfa-2b IFN apparently does not antagonize melphalan or prednisone, nor does it appear to worsen the response of the two drugs alone. Effectiveness of recombinant alfa-2b IFN in pretreated relapsing patients suggests additional trials are needed to study its effects in previously untreated patients. A significant number of patients who relapsed on their original chemotherapy and subsequent interferon will apparently respond to the reinstitution of chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0023269165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023269165&partnerID=8YFLogxK

M3 - Article

C2 - 3296211

AN - SCOPUS:0023269165

VL - 14

SP - 24

EP - 28

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2 SUPPL. 2

ER -